by MM360 Staff | Jun 13, 2025 | Publications
Leuk Lymphoma. 2025 Jun 12:1-11. doi: 10.1080/10428194.2025.2512031. Online ahead of print. ABSTRACT THIS META-ANALYSIS OF EIGHT PHASE 3 RCTS ASSESSED EFFICACY AND SAFETY OF ANTI-CD38 MONOCLONAL ANTIBODIES (MABS) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA...
by MM360 Staff | Jun 6, 2025 | Publications
Clin Lymphoma Myeloma Leuk. 2025 May 14:S2152-2650(25)00159-4. doi: 10.1016/j.clml.2025.05.007. Online ahead of print. ABSTRACT BACKGROUND: The standard treatment for newly diagnosed, transplant-eligible multiple myeloma (NDMM) patients typically involves triplet...
by MM360 Staff | Jun 5, 2025 | Publications
BMC Cancer. 2025 Jun 4;25(1):998. doi: 10.1186/s12885-025-14420-5. ABSTRACT BACKGROUND: Multiple myeloma (MM) is a clonal proliferative disorder of plasma cells with limited curative options. Hepatitis B (HBV) and hepatitis C (HCV) viruses have been implicated in the...
by MM360 Staff | May 28, 2025 | Publications
Front Med (Lausanne). 2025 May 13;12:1575914. doi: 10.3389/fmed.2025.1575914. eCollection 2025. ABSTRACT INTRODUCTION: Multiple myeloma (MM) is a plasma cell malignancy comprising 10% of hematologic cancers, associated with bone marrow dysfunction and organ damage....
by MM360 Staff | May 27, 2025 | Publications
Blood Cancer J. 2025 May 26;15(1):104. doi: 10.1038/s41408-025-01312-x. ABSTRACT While observation is the current standard of care for smoldering multiple myeloma (sMM), emerging evidence suggests that early therapeutic intervention may delay progression and improve...
by MM360 Staff | May 24, 2025 | Publications
Clin Lymphoma Myeloma Leuk. 2025 Apr 3:S2152-2650(25)00105-3. doi: 10.1016/j.clml.2025.03.013. Online ahead of print. ABSTRACT PURPOSE: The increasing use of single-arm and nonrandomized trial designs in oncology aims to expedite patient access to novel treatments. To...
